Compositions containing benzimidazolones and progestogens
CA 2372279 A1 · Owner: Ligand Pharmaceuticals, Inc. · Inventors: Grubb, Gary S.; Bender, Reinhold H. W.; Jones, Todd K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having general structure (1) wherein: A is O S, or NR4; , B is a bond between A and C=Q or the moiety CR5R6; R4, R5, R6 are , independently selected from H or optionally substituted C1 to C6 alkyl C2 to , C6 alkenyl, C2 to C6 alkynyl, C3 to C8 cycloalkyl substituted C3 to C8 , cycloalkyl, aryl or heterocyclic groups, or cyclic alkyl constructed by fusing R4 and R5 to form a 5 to 7 membered ring; R1 is selected from H OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl C3 to C6 alkenyl, substituted , C1 to C6 alkenyl …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 1, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 1, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 1, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.